Mortality Advantage With Pimavanserin in Parkinson's Psychos

Use of pimavanserin was associated with 35% lower mortality for patients with Parkinson's disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.

Related Keywords

United States , American , Pimavanserin Nuplazid , Andrew Mosholder , Acadia Pharmaceuticals , Drug Administration , Drug Evaluation , Medscape Medical , American Journal , Medscape Medical News , Parkinsons Disease , Psychosis , Depression , Atypical Antipsychotics , Schizophrenia , Delusion , Hallucination , Nursing Homes , Us Food And Drug Administration , Nited States Food And Drug Administration , Fda , Off Label Indication ,